Serum levels of IL-32 in patients with coronary artery disease and its relationship with the serum levels of IL-6 and TNF-α
Authors:
- 1 May 2021
- journal article
- research article
- Published by Springer Nature in Molecular Biology Reports
- Vol. 48 (5) , 4263-4271
Abstract
The coronary artery disease (CAD) is a chronic inflammatory disease caused by atherosclerosis, in which arteries become clogged due to plaque formation, fat accumulation, and various sorts of immune cells. IL-32 is a proinflammatory cytokine, which enhances inflammation through inducing the secretion of different inflammatory cytokines. The main objective of the current study was to assess the serum levels of IL-32 in subjects with obstructive CAD and its relationship with the serum levels of IL-6 and TNF-α. This study was performed on 42 subjects with obstructive CAD and 42 subjects with non-obstructive CAD. The serum levels of TNF-α, IL-6, and IL-32 were measured using the enzyme-linked immunosorbent assay (ELISA). The serum levels of TNF-α, IL-6, and IL-32 were 3.2, 3.48, and 2.7 times higher in obstructive CAD compared to non-obstructive CAD, respectively. Moreover, the serum levels of TNF-α and IL-32 in obstructive CAD with cardiac arterial stenosis in one major vessel were significantly higher than the levels in obstructive CAD with cardiac arterial stenosis in more than one major vessel. ROC curve analysis revealed that the serum levels of TNF-α, IL-6, and IL-32 were good predictors of obstructive CAD. Moreover, multiple logistic regression analyses suggested that the serum levels of TNF-α, IL-6, IL-32, LDL, and ox-LDL were independently related to the presence of obstructive CAD, while serum levels of HDL were not. TNF-α, IL-32, and IL-6 showed an increase in obstructive CAD, and the serum levels of these cytokines showed a satisfactory ability for predicting obstructive CAD.Keywords
Funding Information
- Shahrekord University of Medical Sciences (3118)
This publication has 23 references indexed in Scilit:
- Global, regional, and national age–sex specific all-cause and cause-specific mortality for 240 causes of death, 1990–2013: a systematic analysis for the Global Burden of Disease Study 2013The Lancet, 2015
- Towards a role of interleukin-32 in atherosclerosisCytokine, 2013
- Immune Effector Mechanisms Implicated in Atherosclerosis: From Mice to HumansImmunity, 2013
- Cytokines, macrophage lipid metabolism and foam cells: Implications for cardiovascular disease therapyProgress in Lipid Research, 2011
- TNF-alpha stimulates the ACAT1 expression in differentiating monocytes to promote the CE-laden cell formationJournal of Lipid Research, 2009
- Epithelial overexpression of interleukin-32α in inflammatory bowel diseaseClinical and Experimental Immunology, 2007
- IL-32, a proinflammatory cytokine in rheumatoid arthritisProceedings of the National Academy of Sciences, 2006
- IL-32 synergizes with nucleotide oligomerization domain (NOD) 1 and NOD2 ligands for IL-1β and IL-6 production through a caspase 1-dependent mechanismProceedings of the National Academy of Sciences, 2005
- Interleukin-32Immunity, 2005
- A more meaningful scoring system for determining the severity of coronary heart diseaseThe American Journal of Cardiology, 1983